Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction

Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction

Abstract Background No study has compared the cardiovascular outcomes for sodium–glucose cotransporter-2 inhibitors (SGLT2i) head-to-head against other glucose-lowering therapies, including dipeptidyl peptidase 4 inhibitor (DDP4i) or glucagon-like peptide-1 receptor agonist (GLP-1RA)—which also have...

Full description

Bibliographic Details
Main Authors: Jimmy Gonzalez, Benjamin A. Bates, Soko Setoguchi, Tobias Gerhard, Chintan V. Dave
Format: Article
Language:English
Published: BMC 2023-03-01
Series:Cardiovascular Diabetology
Subjects:
Sodium–glucose cotransporter-2 inhibitors
Glucagon-like peptide-1 receptor agonists
Cardiovascular outcomes
Major adverse cardiovascular events
Heart failure
Stroke
Online Access:https://doi.org/10.1186/s12933-023-01784-w

Internet

https://doi.org/10.1186/s12933-023-01784-w

Similar Items